|drug3091||Shared Decision Making Wiki||1.00|
|drug3250||Sublingual Methylene blue Wiki||1.00|
There is one clinical trial.
Within the epidemic context of phase 3 in Mexico, the implementation of new treatments that have been shown to be beneficial for patients in other countries is an urgent need. Methylene blue (MB, the oxidized form, blue color) has been used in many different clinical medicine areas, ranging from malaria to orthopedics. Methylene blue absorbs energy directly from a light source and then transfers this energy to molecules of oxygen creating singlet oxygen (O2), which is the first electronic excited state of molecular oxygen (O2). Singlet oxygen is extremely electrophilic; thus, it can directly oxidize electron-rich double bonds in biological molecules and macromolecules. For this reason, methylene blue has been used as a photosensitizer in the treatment of cancer and the protection of serum from viral agents. Methylene blue can be reactivated using energy from a light source in the body until processed out through the kidneys.
Description: Aretrial oxygen saturation will be taken by an oximeterMeasure: Change form baseline in Arterial oxygen saturation Time: up to 7 days
Description: Number of days of patient dischargeMeasure: Days to clinical improvement Time: up to 7 days
Description: Blood samples will be taken on days 1 and 7Measure: Change Form Baseline in C reactive protein at 7 days Time: up to 7 days
Description: Blood samples to analyse IL-1β will be taken on days 1 and 7.Measure: Change Form Baseline in IL-1β Time: up to 7 days
Description: Blood samples to analyse the Erythrocyte sedimentation rate like procalcitoninMeasure: Change Form Baseline in Erythrocyte sedimentation rate like procalcitonin Time: up to 7 days
Description: Blood samples to analyse Ferritin levelsMeasure: Change Form Baseline in Ferritin levels Time: up to 7 days
Description: Blood samples to analyse D dimer will be taken on days 1 and 7Measure: Change Form Baseline in D dimer Time: up to 7 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports